Cargando…

Application of Perinatal Derivatives in Ovarian Diseases

Reproductive diseases could lead to infertility and have implications for overall health, most importantly due to psychological, medical and socio-economic consequences for individuals and society. Furthermore, economical losses also occur in animal husbandry. In both human and veterinary medicine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange-Consiglio, Anna, Capra, Emanuele, Herrera, Valentina, Lang-Olip, Ingrid, Ponsaerts, Peter, Cremonesi, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818994/
https://www.ncbi.nlm.nih.gov/pubmed/35141212
http://dx.doi.org/10.3389/fbioe.2022.811875
_version_ 1784645958278053888
author Lange-Consiglio, Anna
Capra, Emanuele
Herrera, Valentina
Lang-Olip, Ingrid
Ponsaerts, Peter
Cremonesi, Fausto
author_facet Lange-Consiglio, Anna
Capra, Emanuele
Herrera, Valentina
Lang-Olip, Ingrid
Ponsaerts, Peter
Cremonesi, Fausto
author_sort Lange-Consiglio, Anna
collection PubMed
description Reproductive diseases could lead to infertility and have implications for overall health, most importantly due to psychological, medical and socio-economic consequences for individuals and society. Furthermore, economical losses also occur in animal husbandry. In both human and veterinary medicine, hormonal and surgical treatments, as well as assisted reproductive technologies are used to cure reproductive disorders, however they do not improve fertility. With ovarian disorders being the main reproductive pathology in human and bovine, over the past 2 decades research has approached regenerative medicine in animal model to restore normal function. Ovarian pathologies are characterized by granulosa cell and oocyte apoptosis, follicular atresia, decrease in oocyte quality and embryonic development potential, oxidative stress and mitochondrial abnormalities, ultimately leading to a decrease in fertility. At current, application of mesenchymal stromal cells or derivatives thereof represents a valid strategy for regenerative purposes. Considering their paracrine/autocrine mode of actions that are able to regenerate injured tissues, trophic support, preventing apoptosis and fibrosis, promoting angiogenesis, stimulating the function and differentiation of endogenous stem cells and even reducing the immune response, are all important players in their future therapeutic success. Nevertheless, obtaining mesenchymal stromal cells (MSC) from adult tissues requires invasive procedures and implicates decreased cell proliferation and a reduced differentiation capacity with age. Alternatively, the use of embryonic stem cells as source of cellular therapeutic encountered several ethical concerns, as well as the risk of teratoma formation. Therefore, several studies have recently focussed on perinatal derivatives (PnD) that can be collected non-invasively and, most importantly, display similar characteristics in terms of regenerating-inducing properties, immune-modulating properties and hypo-immunogenicity. This review will provide an overview of the current knowledge and future perspectives of PnD application in the treatment of ovarian hypofunction.
format Online
Article
Text
id pubmed-8818994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88189942022-02-08 Application of Perinatal Derivatives in Ovarian Diseases Lange-Consiglio, Anna Capra, Emanuele Herrera, Valentina Lang-Olip, Ingrid Ponsaerts, Peter Cremonesi, Fausto Front Bioeng Biotechnol Bioengineering and Biotechnology Reproductive diseases could lead to infertility and have implications for overall health, most importantly due to psychological, medical and socio-economic consequences for individuals and society. Furthermore, economical losses also occur in animal husbandry. In both human and veterinary medicine, hormonal and surgical treatments, as well as assisted reproductive technologies are used to cure reproductive disorders, however they do not improve fertility. With ovarian disorders being the main reproductive pathology in human and bovine, over the past 2 decades research has approached regenerative medicine in animal model to restore normal function. Ovarian pathologies are characterized by granulosa cell and oocyte apoptosis, follicular atresia, decrease in oocyte quality and embryonic development potential, oxidative stress and mitochondrial abnormalities, ultimately leading to a decrease in fertility. At current, application of mesenchymal stromal cells or derivatives thereof represents a valid strategy for regenerative purposes. Considering their paracrine/autocrine mode of actions that are able to regenerate injured tissues, trophic support, preventing apoptosis and fibrosis, promoting angiogenesis, stimulating the function and differentiation of endogenous stem cells and even reducing the immune response, are all important players in their future therapeutic success. Nevertheless, obtaining mesenchymal stromal cells (MSC) from adult tissues requires invasive procedures and implicates decreased cell proliferation and a reduced differentiation capacity with age. Alternatively, the use of embryonic stem cells as source of cellular therapeutic encountered several ethical concerns, as well as the risk of teratoma formation. Therefore, several studies have recently focussed on perinatal derivatives (PnD) that can be collected non-invasively and, most importantly, display similar characteristics in terms of regenerating-inducing properties, immune-modulating properties and hypo-immunogenicity. This review will provide an overview of the current knowledge and future perspectives of PnD application in the treatment of ovarian hypofunction. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8818994/ /pubmed/35141212 http://dx.doi.org/10.3389/fbioe.2022.811875 Text en Copyright © 2022 Lange-Consiglio, Capra, Herrera, Lang-Olip, Ponsaerts and Cremonesi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Lange-Consiglio, Anna
Capra, Emanuele
Herrera, Valentina
Lang-Olip, Ingrid
Ponsaerts, Peter
Cremonesi, Fausto
Application of Perinatal Derivatives in Ovarian Diseases
title Application of Perinatal Derivatives in Ovarian Diseases
title_full Application of Perinatal Derivatives in Ovarian Diseases
title_fullStr Application of Perinatal Derivatives in Ovarian Diseases
title_full_unstemmed Application of Perinatal Derivatives in Ovarian Diseases
title_short Application of Perinatal Derivatives in Ovarian Diseases
title_sort application of perinatal derivatives in ovarian diseases
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818994/
https://www.ncbi.nlm.nih.gov/pubmed/35141212
http://dx.doi.org/10.3389/fbioe.2022.811875
work_keys_str_mv AT langeconsiglioanna applicationofperinatalderivativesinovariandiseases
AT capraemanuele applicationofperinatalderivativesinovariandiseases
AT herreravalentina applicationofperinatalderivativesinovariandiseases
AT langolipingrid applicationofperinatalderivativesinovariandiseases
AT ponsaertspeter applicationofperinatalderivativesinovariandiseases
AT cremonesifausto applicationofperinatalderivativesinovariandiseases